Resources - RESEARCH LITERACY
Peptides for weight loss: what the evidence actually shows, compound by compound
Which peptides have real evidence for weight loss and which are running on hype. Semaglutide, tirzepatide and retatrutide trial results; AOD-9604, MOTS-c, tesamorelin, CJC-1295 and ipamorelin examined honestly; how to grade a weight-loss claim; and the UK legal position for each.
Three peptides have solid human evidence for weight loss, and they are all in the same family: semaglutide, tirzepatide and, still in trials, retatrutide. Everything else sold as a weight-loss or fat-burning peptide is running on mechanism, animal data, or the reflected credibility of those three. This article goes compound by compound through what the evidence actually shows, from large trials to mouse studies to nothing at all, explains how to tell the difference when you meet a claim, and sets out where each stands in UK law. It is written for people who have searched for peptides for weight loss and want the real picture. It does not recommend anything. Decisions about weight treatment belong with a prescriber, and the compounds with real evidence are prescription medicines for exactly that reason.
How to grade a weight-loss claim before reading any further
Weight loss is one of the easiest outcomes to make claims about and one of the hardest to prove, because everyone's weight moves, expectations change behaviour, and short studies flatter almost anything. The evidence for any compound sits on a ladder, and where it sits is the whole story.
- Large randomised trials in people, lasting a year or more, with a placebo group and weight as the main outcome. This is the standard. Only the GLP-1 family reaches it.
- Small human studies, short trials, or trials measuring something other than weight, such as a blood marker. Suggestive, not proof.
- Animal studies. Mice made obese on a high-fat diet lose weight on a lot of things that do nothing in people. Interesting, not transferable.
- Mechanism only. "It raises growth hormone, and growth hormone burns fat, so it burns fat." A hypothesis, not a result.
- Testimonials and before-and-after photographs. Not evidence of anything, and, for a medicine, unlawful advertising in the UK.
Hold each compound below against that ladder. The lesson on how Vivera Education grades evidence sets out the same idea in more detail.
Semaglutide: the benchmark
Semaglutide mimics GLP-1, a gut hormone that slows stomach emptying, improves insulin release and reduces appetite. Licensed in the UK as Ozempic for type 2 diabetes and Wegovy for weight management, it is the compound that made "peptides for weight loss" a mainstream phrase. In the STEP 1 trial, 1,961 adults without diabetes took 2.4 mg weekly or placebo for 68 weeks alongside lifestyle support; average weight change was about 14.9% on semaglutide against about 2.4% on placebo, with around a third of the semaglutide group losing 20% or more. Side effects were mainly gastrointestinal. Follow-up trials showed most of the weight returned after stopping. It is a prescription-only medicine, available on the NHS through specialist services under NICE criteria, and otherwise only against a prescription after a clinical assessment. Our separate article covers its dosing, administration and side effects in full.
Tirzepatide: the current high-water mark for a licensed medicine
Tirzepatide acts on both the GLP-1 and GIP receptors. Licensed in the UK as Mounjaro for diabetes and for weight management, it produced the largest weight loss yet seen for a licensed drug: in SURMOUNT-1, 2,539 adults without diabetes lost on average about 15%, 19.5% and 20.9% of body weight at 5 mg, 10 mg and 15 mg weekly over 72 weeks, against about 3.1% on placebo. The side-effect profile matches semaglutide's, dominated by gut effects during escalation. NICE recommended it for weight management in December 2024 with a phased NHS rollout from mid-2025. Prescription-only, and covered in detail in our tirzepatide article.
Retatrutide: real data, no licence
Retatrutide adds a third receptor, glucagon, to the other two. Its phase 2 obesity trial, published in 2023, reported average weight loss of about 24% at the highest dose over 48 weeks in 338 participants, the largest figure yet in a trial of this kind. It is not licensed anywhere, is in phase 3 trials, and has no routine prescribing route. Products sold online as retatrutide are unlicensed, with no check on what they contain. It is the clearest example of a compound whose evidence is genuinely promising and whose availability outside a trial is entirely unregulated; the two facts do not cancel out. Our retatrutide article sets out the trial data and the regulatory position.
AOD-9604: designed for weight loss, failed its trials
AOD-9604 is a fragment of human growth hormone, developed in Australia in the early 2000s specifically as an anti-obesity drug, on the theory that it would carry growth hormone's fat-metabolising effect without its other actions. It went through human trials. They did not show clinically meaningful weight loss, and development for obesity was abandoned. The compound was later sold as a food-supplement ingredient and now circulates as a "fat-burning peptide" in the research-chemical market, where its marketing leans on the original rationale and on animal studies rather than on the human trial results that ended its development. On the evidence ladder it sits at "tested in humans and did not work for this purpose", which is a lower rung than "never tested".
MOTS-c: a genuine research subject, not a treatment
MOTS-c is a short peptide encoded in mitochondrial DNA, discovered in 2015, that appears to act as a metabolic signal. In mice it has been reported to improve insulin sensitivity, increase exercise capacity and protect against diet-induced obesity, and there is intriguing work on how its levels change with age and exercise in people. What there is not is a controlled human trial showing weight loss. The gap between "fascinating mitochondrial biology" and "weight-loss peptide" is the gap between a mouse and a person, and it has not been crossed. Sold as a research chemical; no licence; no human dose.
Tesamorelin: licensed, but not for this
Tesamorelin is a growth-hormone-releasing hormone analogue that is licensed in some countries, though not the UK, for reducing excess abdominal fat in people with HIV-associated lipodystrophy, a specific medical condition. Its trials in that population showed a modest reduction in visceral fat, not general weight loss, and the effect reversed on stopping. It is sometimes marketed as a fat-loss peptide for the general population on the strength of that licence. The licence is real; the extrapolation is not supported, and in the UK the product has no marketing authorisation at all.
CJC-1295, ipamorelin and the growth-hormone secretagogues
These compounds stimulate the body's own growth-hormone release, and because growth hormone influences body composition, they are marketed for fat loss and lean mass. The chain of reasoning is a mechanism, not a result. Controlled human trials showing meaningful fat or weight loss from CJC-1295, ipamorelin or their combination do not exist; the human data that do exist mostly measure hormone levels over short periods. Their legal position in the UK is that of research chemicals: lawful to supply for laboratory use, unlawful to sell for people to take. The classroom lesson on growth-hormone secretagogues explains the biology and the evidence gap.
5-Amino-1MQ and the compounds that are not peptides at all
Some products sold in the "weight-loss peptide" aisle are not peptides. 5-Amino-1MQ is a small molecule that inhibits an enzyme involved in fat-cell metabolism; it has rodent data and no human trials. It appears here because it is sold alongside peptides and searched for with them, and because it illustrates how loose the category has become: "peptide" is being used as a marketing label for anything injectable or capsule-shaped sold through the same channels.
Why real results for one class became hype for all of them
The GLP-1 medicines did something rare: they produced large, reproducible, well-documented weight loss in trials of thousands of people, and they did it recently, in public, with celebrities and headlines. That credibility has been borrowed wholesale. A market that sells semaglutide has an obvious incentive to sell other peptides next to it with the same vocabulary, and a reader who has seen the GLP-1 results is primed to believe the next peptide works too. Evidence does not transfer that way. Each compound has to earn its own trials, and most of the compounds in this article have not.
The UK legal position, compound by compound
- Semaglutide and tirzepatide: licensed prescription-only medicines. Lawful through a prescriber and pharmacy; unlawful to sell without a prescription or to advertise to the public. "Research grade" versions sold online are unlicensed.
- Retatrutide: no licence anywhere. No routine prescribing route. Anything sold is unlicensed.
- AOD-9604, MOTS-c, CJC-1295, ipamorelin, 5-Amino-1MQ: not licensed medicines. They may be supplied for genuine laboratory research, but there is no research-use exemption in UK law: the MHRA judges each product on how it is presented, and selling or presenting them for people to use makes them unauthorised medicines, an offence for the seller.
- Tesamorelin: licensed in some countries for a specific condition, not in the UK.
Our article on whether peptides are legal in the UK explains the framework behind those positions.
What this means if you are trying to lose weight
It means the honest list is short. The peptide-based treatments that work are medicines, they are prescribed, they come with monitoring and side effects, and they need to be continued. In the UK they are prescribed after a clinical assessment; a GP is the starting point. Everything else sold under the same banner is, at best, an early research subject and, at worst, a failed drug with a new label. Knowing that is not a reason for despair; it is the difference between spending money on something with a 68-week trial behind it and something with a mouse.
This article is educational content only and is not medical advice, diagnosis or a recommendation to use any compound or medicine. Trial figures describe monitored clinical trials of licensed or investigational medicines and are not instructions for use. Anyone considering treatment for weight should speak to a GP or other qualified prescriber. Vivera Education sells nothing.
Frequently asked
- Which peptides actually work for weight loss?
- The ones with large human trials behind them are the GLP-1-based medicines: semaglutide (about 15% average weight loss over 68 weeks in its main trial), tirzepatide (15% to 21% over 72 weeks) and, still in trials, retatrutide (up to about 24% over 48 weeks in phase 2). No other peptide sold for weight loss has controlled human evidence of meaningful weight loss.
- Does AOD-9604 work for weight loss?
- It was developed as a weight-loss drug, but its human trials did not show clinically meaningful weight loss and development for that purpose stopped. Its later marketing as a fat-burning peptide rests on the original rationale and animal work, not on human results.
- Does MOTS-c help with weight loss?
- MOTS-c is a peptide encoded in mitochondrial DNA that has shown metabolic effects in mice, including resistance to diet-induced obesity. There are no peer-reviewed controlled human trials showing weight loss in people. It is an interesting research subject, not a proven treatment.
- Do CJC-1295 and ipamorelin cause fat loss?
- They stimulate growth-hormone release, and growth hormone affects body composition, so a mechanism exists. Controlled human trials showing meaningful fat or weight loss from these compounds do not. Claims about them rest on the mechanism, not on outcomes.
- What is the best peptide for weight loss in the UK?
- For someone in the UK, the only peptide-based weight-loss treatments with evidence and a licence are semaglutide (Wegovy) and tirzepatide (Mounjaro), both prescription-only and prescribed with lifestyle support. Everything else is either unlicensed, unproven in humans, or both.
- Are weight-loss peptides legal in the UK?
- Semaglutide and tirzepatide are legal as prescription-only medicines, prescribed and dispensed through regulated routes; selling them without a prescription or advertising them to the public is an offence. Research peptides such as AOD-9604 and MOTS-c may be supplied for genuine laboratory research, with no research-use exemption in law, and not sold for people to use. Retatrutide has no licence anywhere.
- Why is there so much hype around peptides for fat loss?
- Because the GLP-1 medicines produced genuinely large, well-documented results, and that credibility has been borrowed by unrelated compounds sold through the same channels. A real result for one class of peptide does not transfer to another; each compound has to earn its own evidence.
- Does weight come back after stopping?
- In the follow-up trials for semaglutide and tirzepatide, most people regained a large part of the lost weight within a year of stopping. That is why they are licensed as ongoing treatments alongside diet and activity rather than as courses.
- Are peptides like Ozempic?
- The active ingredient in Ozempic, semaglutide, is itself a peptide: a modified chain of 31 amino acids. It is licensed in the UK for type 2 diabetes, and the same ingredient is licensed for weight management as Wegovy. The real distinction is between licensed peptide medicines, which have large trials of the actual product and regulated manufacture, and unlicensed peptides sold online, where nobody has checked what is in the vial and most of the compounds have no large human trials at all.
The studies and sources behind this page
Lessons on this topic
Related reading
Educational content only. Not medical advice, diagnosis or treatment. Always consult a qualified healthcare professional before changing your health regimen.